Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the asia-pacific region: A systematic review

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wong, Martin C S ^a   Wang, Harry H X ^a,b   Kwan, Mandy W M ^a   Zhang, Daisy D X ^a   Liu, Kirin Q L ^a   Chan, Sky W M ^a   Fan, Carmen K M ^a   Fong, Brian C Y ^a   Li, Shannon T S ^a   Griffiths, Sian M ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALOGLIPTIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; ADD ON THERAPY; BLOATING; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; LACTIC ACIDOSIS; NAUSEA; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ASIA; DIABETES MELLITUS, TYPE 2; META ANALYSIS; PACIFIC OCEAN;

ASIA; COMPARATIVE EFFECTIVENESS RESEARCH; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PACIFIC OCEAN; SULFONYLUREA COMPOUNDS;

EID: 84897543045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090963     Document Type: Review

References (64)

1. Feinglos MN, Bethel MA (2008) Type 2 diabetes mellitus : an evidence-based approach to practical management. Totowa, NJ: Humana Press.
2. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, et al. (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29(6):1263-1268. (Pubitemid 44125920)
3. Castell C, Tresserras R, Serra J, Goday A, Lloveras G, et al. (1999) Prevalence of diabetes in Catalonia (Spain): an oral glucose toleratence test-based population study. Diabetes Res Clin Pract 43(1): 33-40. (Pubitemid 29096409)
4. Lopatynski J, Mardarowicz G, Nicer T, Szczesniak G, Hrol H, et al. (2001) The prevalence of type II diabetes mellitus in rural urban population over 35 years of age in Lublin region (Eastern Poland). Polskie Archiwum Medycyny Wewnetrznej106(3):781-786.
5. Wong MC, Leung MC, Tsang CS, Lo SV, Griffiths SM (2013) The rising tide of diabetes mellitus in a Chinese population: a population-based household survey on 121,895 persons. Int J Public Health 58(2):269-276.
6. Yang W, Lu J, Weng J, Jia WP, Ji LN, et al. (2010) Prevalence of diabetes among men and women in China. NEJM 362(12): 1090-1101.
7. International Diabetes Federation Diabetes Atlas Fifth Edition (2012) Available: http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 27 August 2013.
8. Diabetes Statistics American Diabetes Association (2011) Available: http://www.diabetes.org/diabetes-basics/diabetes-statistics.Accessed 27 August 2013.
9. World Health Organization. Diabetes Atlas : Western Pacific Region (2012) Available: http://www.idf.org/diabetesatlas/?menu-id=2008417121010. Accessed 27 August 2013.
10. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321(7258): 412-419. (Pubitemid 30609443)
11. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2005) Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28(12): 2901-2907. (Pubitemid 43942922)
12. Van Dijk CE, Hoekstra T, Verheij RA, Twisk JW, Groenewegen PP, et al. (2013) Type II diabetes patients in primary care: profiles of healthcare utilization obtained from observational data. BMC Health Serv Res 13:7.
13. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, et al.(2004) Management of Diabetes and Hyperglycemia in Hospitals. Diabetes Care 27(2):553-591. (Pubitemid 38174086)
14. Sicree R, Shaw J, Zimmet P (2009) The Global Burden - Diabetes and Impaired Glucose Tolerance. Baker IDI Heart and Diabetes Institute. Available: http://www.idf.org/sites/default/files/The-Global-Burden.pdf. Accessed 27 August 2013.
15. Gareth W (1994) Management of non-insulin-dependent diabetes mellitus. Lancet 343(8889): 95-100.
16. DeFronzo RA, Goodman AM, the Multicenter Metformin Study Group (1995) Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus. N Engl J Med 333: 541-549.
17. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med. 334(9): 574-579. (Pubitemid 126537875)
18. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131): 854-865.
19. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333(9): 550-554.
20. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103(6): 491-497. (Pubitemid 28018651)
21. Groop L, Groop PH, Stenman S, Saloranta C, Totterman KJ, et al. (1987) Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 10(6): 671-678. (Pubitemid 18049818)
22. Rosenstock J, Samols E, Muchmore DB, Schneider J (1996) Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19(11): 1194-1199.
23. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT (1997) Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 20(4): 597-606. (Pubitemid 27143421)
24. Schade DS, Jovanovic L, Schneider J (1998) A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmaco l38(7): 636-641. (Pubitemid 28354902)
25. Levetan C (2007) Oral antidiabetic agents in type 2 diabetes. Curr med Res Opin 23(4): 945-952.
26. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2007) Glycemic durability or rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23): 2427-2443.
27. Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27(8): 1102-1110. (Pubitemid 47173656)
28. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131): 837-853.
29. Eldor R, Raz I (2012) Diabetes therapy-focus on Asia: second-line therapy debate: insulin/secretagogues. Diabetes Metab Res Rev (Suppl 2): 85-89.
30. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, et al. (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23(11): 1605-1611.
31. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 355(23): 2427-2443. (Pubitemid 44903747)
32. Guan Y, Hao C, Cha DR, Rao R, Lu W, et al. (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11(8): 861-866. (Pubitemid 41161118)
33. Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170(14): 1191-1201.
34. Owens DR, Zinman B, Bolli GB (2001) Insulins today and beyond. Lancet 358(9283): 739-746. (Pubitemid 32823407)
35. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414(6865): 799-806. (Pubitemid 34000783)
36. Guisasola FA, Mavros P, Nocea G, Alemao E, Alexander CM, et al. (2008) Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 10(Suppl.1): 8-15.
37. Zhang SL, Chen ZC, Li Y, Chen LH, Cheng H, et al. (2011) Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. Chin Med J (Engl) 124(16): 2461-2468.
38. Yan BI, Yan JH, Liao ZH, Li YB, Zeng LY, et al. (2008) Inadequate glycaemic control and antidiabetic therapy among inpatients with type 2 diabetes in Guangdong Province of China. Chin Med J (Engl) 121(8): 677-681.
39. Task Force on Conceptual Model and Preventive Protocols, Working Group on Primary Care, Food and Health Bureau (2010) Module 6, Drug Treatment for Hyperglycaemia, Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care Setting. Available: http://www.pco.gov.hk/english/resource/files/ professionals-DM-Module6.pdf. Accessed 27 August 2013.
40. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, et al. (2013) Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev (10).
41. Barnett AH, Grice J (2011) Chapter 4, New Mechanisms in Glucose Control, Oxford: Wiley-Blackwell.
42. Mest H J, Mentlein R (2005) Dipeptidyl peptidase inhibitors as a new drugs for the treatment of type 2 diabetes. Diabetolgia 48(4): 616-620.
43. Mohan V, Yang WY, Son HY, Xu L, Noble L, et al. (2009) Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 83(1): 106-116.
44. Green BD, Flatt PR, Bailey CJ (2006) Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res 3: 159-65. (Pubitemid 44902481)
45. Barnett AH, Grice J (2011) Chapter 5, New Mechanisms in Glucose Control. Oxford: Wiley-Blackwell.
46. Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ (2010) Textbook of diabetes, 4th edition, Oxford, UK: Wiley-Blackwell.
47. FDA Drug Safety Podcast: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available: http://www.fda.gov/Drugs/ DrugSafety/DrugSafetyPodcasts/ucm344232.htm/. Accessed 27 August 2013.
48. Kaku K, Rasmussen MF, Clauson P, Seino Y (2010) Improved glycaemic control withminimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12(4): 341-347.
49. Seino Y, Rasmussen MF, Clauson P, Kaka K (2012) The once-daily human glucagon-like peptide-1 analog, liraglutide, improves beta-cell function in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation 3(4):388-395.
50. Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, et al. (2011) Improved glycemic control and reducedbodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. Journal of Diabetes Investigation 2(3):210-217.
51. Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T (2012) Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study. Clinical Therapeutics 34(9):1892-1908.e1.
52. Seino Y, Niemoeller E, Takami A, EFC10887 GETGOAL-L Asia study Investigators, et al. (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes, Obesity and Metabolism 14(10): 910-917.
53. Inagaki N, Watada H, Murai M, Kagimura T, Gong Y, et al. (2013) Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1year in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 15(9): 833-843.
54. Zeng Z, Yang JK, Tong N, Yan S, Zhang X, et al. (2013) Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: A sub-analysis of data from a randomised clinical trial. Current Medical Research and Opinion 29(8): 921-929.
55. Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, et al. (2013) Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: The COMPASS randomized controlled trial. Diabetes, Obesity and Metabolism 15(5): 455-462.
56. Seino Y., Hiroi S., Hirayama M., Kaku K (2012) Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Journal of Diabetes Investigation 3(6): 517-525.
57. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Dipeptidyl peptidase (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2).
58. Chan CN, Malik V, Jia Weiping, Kadowaki T, Yajnik CS, et al. (2009) Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology. JAMA 301(20): 2129-2140.
59. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, et al. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibiros between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56(4): 696-708.
60. Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, et al. (2013) Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 29(5): 417-426.
61. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14): 1317-1326.
62. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, et al. (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14): 1327-1335.
63. Kawamori R (2002) Diabetes trends in Japan. Diabetes Metab Res Rev 18 Suppl: S9-S13.
64. Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, et al. (2006) The status of diabetes control and antidiabetic drug therapy in Japan - a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 73(2):198-204. (Pubitemid 43928164)